To participate in the GOLDN study, participants were required to be identified through families previously screened in the NHLBI FHS Minnesota or Utah centers. Because FHS was conducted exclusively in participants of Caucasian descent, the GOLDN population is entirely white, and this was scientifically acceptable when originally funded because (a) the source cohort was all of Caucasian descent and (b) PROGENI as a program had representation from other ethnic groups. For GOLDN, eligible family members were 18 years of age or older, had fasting triglycerides < 1500 mg/dL, were in a family with at least two members in a sibship, had normal liver function tests (i.e., aspartate transaminase and alanine transaminase tests within normal range), and creatinine values ≤ 2.0. Anyone with a history of liver, kidney, pancreas, gall bladder disease or malabsorption was excluded, as were pregnant women or women of childbearing potential not using an acceptable form of contraception, or anyone requiring insulin to treat diabetes. Individuals using hypolipidemic drugs were asked to consult with their physician and were taken off medications at least four weeks prior to the study after informed consent for drug withdrawal was obtained. Participants in the current study provided written informed consent to DNA sharing options that allowed future research to be conducted from stored specimens.
Item
To participate in the GOLDN study, participants were required to be identified through families previously screened in the NHLBI FHS Minnesota or Utah centers. Because FHS was conducted exclusively in participants of Caucasian descent, the GOLDN population is entirely white, and this was scientifically acceptable when originally funded because (a) the source cohort was all of Caucasian descent and (b) PROGENI as a program had representation from other ethnic groups. For GOLDN, eligible family members were 18 years of age or older, had fasting triglycerides < 1500 mg/dL, were in a family with at least two members in a sibship, had normal liver function tests (i.e., aspartate transaminase and alanine transaminase tests within normal range), and creatinine values ≤ 2.0. Anyone with a history of liver, kidney, pancreas, gall bladder disease or malabsorption was excluded, as were pregnant women or women of childbearing potential not using an acceptable form of contraception, or anyone requiring insulin to treat diabetes. Individuals using hypolipidemic drugs were asked to consult with their physician and were taken off medications at least four weeks prior to the study after informed consent for drug withdrawal was obtained. Participants in the current study provided written informed consent to DNA sharing options that allowed future research to be conducted from stored specimens.
boolean
C0947630 (UMLS CUI [1,1])
C0679646 (UMLS CUI [1,2])
C0205396 (UMLS CUI [1,3])
C2064690 (UMLS CUI [1,4])
C1955970 (UMLS CUI [1,5])
C0026183 (UMLS CUI [1,6])
C0042124 (UMLS CUI [1,7])
C4704895 (UMLS CUI [1,8])
C0679646 (UMLS CUI [1,9])
C0007457 (UMLS CUI [1,10])
C1879533 (UMLS CUI [1,11])
C5441552 (UMLS CUI [1,12])
C0086282 (UMLS CUI [1,13])
C0001779 (UMLS CUI [1,14])
C2874288 (UMLS CUI [1,15])
C0438235 (UMLS CUI [1,16])
C0004002 (UMLS CUI [1,17])
C0001899 (UMLS CUI [1,18])
C0010294 (UMLS CUI [1,19])
C0455550 (UMLS CUI [1,20])
C0455686 (UMLS CUI [1,21])
C0558976 (UMLS CUI [1,22])
C0683519 (UMLS CUI [1,23])
C0030286 (UMLS CUI [1,24])
C3714745 (UMLS CUI [1,25])
C0033011 (UMLS CUI [1,26])
C4324275 (UMLS CUI [1,27])
C0680251 (UMLS CUI [1,28])
C2919192 (UMLS CUI [1,29])
C4227726 (UMLS CUI [1,30])
C0086440 (UMLS CUI [1,31])
C0548440 (UMLS CUI [1,32])
C5421123 (UMLS CUI [1,33])
C0021430 (UMLS CUI [1,34])
C1546942 (UMLS CUI [1,35])
C0012854 (UMLS CUI [1,36])
C0035168 (UMLS CUI [1,37])